



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



AM095

Item No. 22141

CAS Registry No.: 1228690-36-5
Formal Name: 4'-[3-methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazoly]-[1,1'-biphenyl]-4-acetic acid
MF: C₂₇H₂₄N₂O₅
FW: 456.5
Purity: ≥95%
UV/Vis.: λ_{max}: 297 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AM095 is supplied as a crystalline solid. A stock solution may be made by dissolving the AM095 in the solvent of choice, which should be purged with an inert gas. AM095 is soluble in the organic solvent DMSO.

Description

AM095 is an orally bioavailable antagonist of lysophosphatidic acid receptor 1 (LPA₁) with IC₅₀ values of 25 and 23 nM in CHO cells expressing human or mouse receptors, respectively.¹ It is selective for LPA₁ over LPA₂, LPA₃, LPA₄, and LPA₅ (IC₅₀s = >10,000 nM for human LPA₂₋₅). It inhibits chemotaxis of CHO cells overexpressing LPA₁ and of A2058 human melanoma cells (IC₅₀s = 778 and 233 nM, respectively) and prevents LPA-induced increases in plasma histamine levels in mice (ED₅₀ = 8.3 mg/kg).² It also decreases collagen and protein levels in bronchoalveolar lavage fluid (BALF) in a mouse model of bleomycin-induced lung injury (ED₅₀s = ~10 mg/kg for both) and decreases kidney fibrosis in a mouse model of unilateral ureteral obstruction when administered at a dose of 30 mg/kg for eight days.

References

1. Castelino, F.V., Seiders, J., Bain, G., *et al.* Genetic deletion or pharmacologic antagonism of LPA₁ ameliorates dermal fibrosis in a scleroderma mouse model. *Arthritis Rheum.* **63(5)**, 1405-1415 (2011).
2. Swaney, J.S., Chapman, C., Correa, L.D., *et al.* Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. *J. Pharmacol. Exp. Ther.* **336(3)**, 693-700 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/07/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM